Drug Profile
KA 2507
Alternative Names: HDAC6 inhibitor - Karus Therapeutics; HDAC6i - Karus Therapeutics; KA-2507Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Karus Therapeutics
- Developer Karus Therapeutics; University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Depsipeptides; Small molecules
- Mechanism of Action HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Biliary cancer; Haematological malignancies; Solid tumours
Most Recent Events
- 28 Sep 2022 Discontinued - Phase-I for Solid tumours (Late-stage disease, Monotherapy, Second-line therapy or greater) in USA (PO) (Karus Therapeutics website, September 2022).
- 28 Sep 2022 Discontinued - Phase-II for Biliary cancer (Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in United Kingdom (PO) (Karus Therapeutics website, September 2022).
- 28 Sep 2022 Discontinued - Preclinical for Haematological malignancies in USA (PO) (Karus Therapeutics website, September 2022).